Litsea japonica extract inhibits neuronal apoptosis and the accumulation of advanced glycation end products in the diabetic mouse retina

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 1075-1081

  Kim, Junghyun ^a   Kim, Chan Sik ^a   Lee, Yun Mi ^a   Sohn, Eunjin ^a   Jo, Kyuhyung ^a   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Advanced glycation end products; Diabetic retinopathy; Litsea japonica; Retinal ganglion cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LITSEA JAPONICA EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DNA BINDING; GEL MOBILITY SHIFT ASSAY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LITSEA; LITSEA JAPONICA; MALE; MOUSE; NICK END LABELING; NONHUMAN; RETINA GANGLION CELL; RETINA NEUROEPITHELIAL LAYER; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

LITSEA JAPONICA; MUS;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; GLYCOSYLATION END PRODUCTS, ADVANCED; LITSEA; MALE; MICE; MICE, TRANSGENIC; NF-KAPPA B; PLANT EXTRACTS; RETINAL GANGLION CELLS;

EID: 84926611314     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3543     Document Type: Article

References (40)

1. Mizutani M, Kern TS and Lorenzi M: Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 97: 2883-2890, 1996.
2. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A and Lorenzi M: A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 52: 506-511, 2003.
3. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG and Gardner TW: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102: 783-791, 1998.
4. Kern TS and Barber AJ: Retinal ganglion cells in diabetes. J Physiol 586: 4401-4408, 2008.
5. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223-234, 1995.
6. Koga K, Yamagishi S, Okamoto T, et al.: Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res 22: 13-17, 2002.
7. Miura J, Yamagishi S, Uchigata Y, et al.: Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 17: 16-21, 2003.
8. Hammes HP, Alt A, Niwa T, et al.: Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42: 728-736, 1999.
9. Lecleire-Collet A, Tessier LH, Massin P, et al.: Advanced glycation end products can induce glial reaction and neuronal degeneration in retinal explants. Br J Ophthalmol 89: 1631-1633, 2005.
10. Kasper M, Roehlecke C, Witt M, et al.: Induction of apoptosis by glyoxal in human embryonic lung epithelial cell line L132. Am J Respir Cell Mol Biol 23: 485-491, 2000.
11. Kaji Y, Amano S, Usui T, et al.: Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci 44: 521-528, 2003.
12. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M and Makita Z: Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 296: 877-882, 2002.
13. Deane R, Du Yan S, Submamaryan RK, et al.: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913, 2003.
14. Hammes HP, Martin S, Federlin K, Geisen K and Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558, 1991.
15. Kern TS and Engerman RL: Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 50: 1636-1642, 2001.
16. Kern TS, Tang J, Mizutani M, et al.: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41: 3972-3978, 2000.
17. Vasan S, Foiles PG and Founds HW: Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 10: 1977-1987, 2001.
18. Harris CS, Beaulieu LP, Fraser MH, et al.: Inhibition of advanced glycation end product formation by medicinal plant extracts correlates with phenolic metabolites and antioxidant activity. Planta Med 77: 196-204, 2011.
19. Lee SY, Min BS, Kim JH, et al.: Flavonoids from the leaves of Litsea japonica and their anti-complement activity. Phytother Res 19: 273-276, 2005.
20. Min BS, Lee SY, Kim JH, et al.: Lactones from the leaves of Litsea japonica and their anti-complement activity. J Nat Prod 66: 1388-1390, 2003.
21. Sohn EJ, Kim J, Kim CS, et al.: The extract of Litsea japonica reduced the development of diabetic nephropathy via the inhibition of advanced Glycation end products accumulation in db/db mice. Evid-Based Compl Alt Med 2013: 769416, 2013.
22. Sohn EJ, Kim CS, Kim YS, et al.: Effects of magnolol (5,5′-diallyl-2,2′-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. Life Sci 80: 468-475, 2007.
23. Hernández-Presa MA, Gómez-Guerrero C and Egido J: In situ non-radioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Kidney Int 55: 209-214, 1999.
24. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T and Inoue H: Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 579: 4265-4270, 2005.
25. Romeo G, Liu WH, Asnaghi V, Kern TS and Lorenzi M: Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51: 2241-2248, 2002.
26. Kowluru RA, Koppolu P, Chakrabarti S and Chen S: Diabetes-induced activation of nuclear transcriptional factor in the retina and its inhibition by antioxidants. Free Radic Res 37: 1169-1180, 2003.
27. Hammes HP, Federoff HJ and Brownlee M: Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1: 527-534, 1995.
28. Kerrigan LA, Zack DJ, Quigley HA, Smith SD and Pease ME: TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol 115: 1031-1035, 1997.
29. Chiarelli F, Catino M, Tumini S, et al.: Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr Nephrol 14: 841-846, 2000.
30. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K and Tsukada Y: Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 41: 131-137, 1998.
31. Funk RH and Schmidt KG: Characteristic features of optic nerve ganglion cells and approaches for neuroprotection. From intracellular to capillary processes and therapeutic considerations. Ophthalmologe 101: 1062-1070, 2004 (In German).
32. Yamagishi S, Hsu CC, Taniguchi M, et al.: Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 213: 681-687, 1995.
33. Yamagishi S, Amano S, Inagaki Y, et al.: Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 290: 973-978, 2002.
34. Yamagishi S, Nakamura K and Matsui T: Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol 3: 83-88, 2006.
35. Lee EH, Song DG, Lee JY, Pan CH, Um BH and Jung SH: Flavonoids from the leaves of Thuja orientalis inhibit the aldose reductase and the formation of advanced glycation endproducts. J Korean Soc Appl Biol Chem 52: 448-455, 2009.
36. Jang DS, Kim JM, Lee YM, et al.: Flavonols from Houttuynia cordata with protein Glycation and Aldose reductase inhibitory activity. Nat Prod Sci 12: 210-213, 2006.
37. Matsuda H, Wang T, Managi H and Yoshikawa M: Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg Med Chem 11: 5317-5323, 2003.
38. Kim J, Kim KM, Kim CS, et al.: Puerarin inhibits the retinal pericyte apoptosis induced by advanced glycation end products in vitro and in vivo by inhibiting NADPH oxidase-related oxidative stress. Free Radic Biol Med 53: 357-365, 2012.
39. Wu T, Chiang SK, Chau FY and Tso MO: Light-induced photoreceptor degeneration may involve the NF kappaB/caspase-1 pathway in vivo. Brain Res 967: 19-26, 2003.
40. Choi JS, Kim JA, Kim DH, et al.: Failure to activate NF-kappaB promotes apoptosis of retinal ganglion cells following optic nerve transection. Brain Res 883: 60-68, 2000.